Longitudinal tumor size measurements from the OAK clinical trial, a Phase III study comparing atezolizumab (MPDL3280A) with docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Patients were matched to those in os_data using baseline SLD, treatment arm, and best overall response. Only patients with at least 3 tumor size measurements are included.
Format
A tibble with one row per tumor measurement and 4 columns:
- id
Patient identifier (factor), matched to os_data
- year
Time of measurement in years from treatment start (numeric)
- sld
Sum of longest diameters of target lesions in mm (numeric)
- arm
Treatment arm (factor):
"Docetaxel"or"MPDL3280A"
Source
Tumor size measurements extracted from the S1 dataset of: Ghaffari Laleh N, Loeffler CML, Grajek J, Staňková K, Pearson AT, Muti HS, et al. (2022). Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol 18(2): e1009822. https://doi.org/10.1371/journal.pcbi.1009822
Data preparation code adapted from: Sabanes Bove D and Mercier F. https://rconis.github.io/tgi-os-training/